SG10201911558UA - Dioxolane analogues of uridine for the treatment of cancer - Google Patents

Dioxolane analogues of uridine for the treatment of cancer

Info

Publication number
SG10201911558UA
SG10201911558UA SG10201911558UA SG10201911558UA SG10201911558UA SG 10201911558U A SG10201911558U A SG 10201911558UA SG 10201911558U A SG10201911558U A SG 10201911558UA SG 10201911558U A SG10201911558U A SG 10201911558UA SG 10201911558U A SG10201911558U A SG 10201911558UA
Authority
SG
Singapore
Prior art keywords
uridine
cancer
treatment
dioxolane
analogues
Prior art date
Application number
SG10201911558UA
Other languages
English (en)
Inventor
Richard Bethel
Anders Eneroth
Björn Klasson
Fredrik ÖBERG
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of SG10201911558UA publication Critical patent/SG10201911558UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG10201911558UA 2014-08-25 2015-08-24 Dioxolane analogues of uridine for the treatment of cancer SG10201911558UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1450983 2014-08-25
SE1550858 2015-06-22

Publications (1)

Publication Number Publication Date
SG10201911558UA true SG10201911558UA (en) 2020-01-30

Family

ID=54014804

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201911558UA SG10201911558UA (en) 2014-08-25 2015-08-24 Dioxolane analogues of uridine for the treatment of cancer
SG10202001117YA SG10202001117YA (en) 2014-08-25 2015-08-24 Dioxolane analogues of uridine for the treatment of cancer
SG11201701172SA SG11201701172SA (en) 2014-08-25 2015-08-24 Dioxolane analogues of uridine for the treatment of cancer

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10202001117YA SG10202001117YA (en) 2014-08-25 2015-08-24 Dioxolane analogues of uridine for the treatment of cancer
SG11201701172SA SG11201701172SA (en) 2014-08-25 2015-08-24 Dioxolane analogues of uridine for the treatment of cancer

Country Status (24)

Country Link
US (7) US10144750B2 (enrdf_load_html_response)
EP (2) EP3572410B1 (enrdf_load_html_response)
JP (2) JP6663424B2 (enrdf_load_html_response)
KR (2) KR102396905B1 (enrdf_load_html_response)
CN (4) CN110790789B (enrdf_load_html_response)
AU (2) AU2015308988C1 (enrdf_load_html_response)
BR (1) BR112017003898B1 (enrdf_load_html_response)
CA (2) CA3128645C (enrdf_load_html_response)
CY (1) CY1122945T1 (enrdf_load_html_response)
DK (2) DK3572410T3 (enrdf_load_html_response)
EA (2) EA031106B1 (enrdf_load_html_response)
ES (2) ES2796089T3 (enrdf_load_html_response)
HR (1) HRP20201023T1 (enrdf_load_html_response)
HU (2) HUE050705T2 (enrdf_load_html_response)
IL (2) IL250344B (enrdf_load_html_response)
MX (1) MX369649B (enrdf_load_html_response)
MY (2) MY188089A (enrdf_load_html_response)
NZ (2) NZ762628A (enrdf_load_html_response)
PH (2) PH12017500184A1 (enrdf_load_html_response)
PL (2) PL3572410T3 (enrdf_load_html_response)
PT (2) PT3572410T (enrdf_load_html_response)
SG (3) SG10201911558UA (enrdf_load_html_response)
WO (1) WO2016030335A1 (enrdf_load_html_response)
ZA (1) ZA201802864B (enrdf_load_html_response)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3572410T (pt) 2014-08-25 2022-09-15 Medivir Ab Análogos dioxolano de uridina para o tratamento de cancro
CN106543220A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
SMT202100665T1 (it) 2015-12-11 2022-03-21 NuCana plc Sintesi diastereoselettiva di derivati di fosfato e del profarmaco di gemcitabina nuc-1031
AU2017227516B2 (en) * 2016-03-02 2022-03-03 Medivir Aktiebolag Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
CN106432328B (zh) * 2016-09-14 2019-03-22 江苏福瑞生物医药有限公司 一种索非布韦中间体的制备方法
CA3043437A1 (en) * 2016-11-18 2018-05-24 Neurovive Pharmaceutical Ab Liver prodrugs of mitochondrial proton ionophores
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
JP7337539B2 (ja) * 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド
WO2019245444A1 (en) 2018-06-21 2019-12-26 Medivir Ab Base-modified cytidine nucleotides for leukemia therapy
CA3129585A1 (en) * 2019-02-18 2020-08-27 Medivir Aktiebolag Methods for treating liver cancers using an orally administered dioxolane nucleotide in combination with an anti-pd1 or anti-pdl1 monoclonal antibody
CN110964057B (zh) * 2019-12-25 2022-05-06 东南大学 一种利用微流体反应装置制备索非布韦中间体的方法
CN113402546A (zh) * 2020-03-17 2021-09-17 浙江四维医药科技有限公司 一种瑞德西韦磷酸中间体尾链动态动力学拆分方法
HRP20250669T1 (hr) * 2020-04-15 2025-08-01 Medivir Ab Miv-818/lenvatinib kombinirana terapija za rak jetre
CN113754692B (zh) * 2020-06-03 2022-06-10 上海交通大学 瑞德西韦中间体(s,s)-氨基磷酸酯的不对称催化合成方法
CN114685558A (zh) * 2020-12-28 2022-07-01 尚科生物医药（上海）有限公司 一种瑞德西韦中间体的制备方法
CN114249764A (zh) * 2021-11-10 2022-03-29 宁波大学 一种磷酰胺酯类前药的中间体及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
AU1201502A (en) * 2000-10-13 2002-04-22 Shire Biochem Inc Dioxolane analogs for improved inter-cellular delivery
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2007106450A2 (en) * 2006-03-10 2007-09-20 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase in combination therapy
CN101534835B (zh) * 2006-09-01 2012-05-30 佐治亚大学研究基金会 用于癌症的L-OddC的前药
PL216525B1 (pl) * 2006-10-17 2014-04-30 Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk 5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
JP2017504572A (ja) 2013-11-27 2017-02-09 アイデニクス・ファーマシューティカルズ・エルエルシー 肝臓癌治療のためのヌクレオチド類
PT3572410T (pt) * 2014-08-25 2022-09-15 Medivir Ab Análogos dioxolano de uridina para o tratamento de cancro

Also Published As

Publication number Publication date
IL266766B (en) 2020-05-31
SG10202001117YA (en) 2020-04-29
PH12019501919A1 (en) 2020-09-14
MX2017002328A (es) 2017-05-22
CA3128645A1 (en) 2016-03-03
CY1122945T1 (el) 2021-10-29
AU2015308988A1 (en) 2017-02-23
AU2018201980A1 (en) 2018-04-12
PL3572410T3 (pl) 2022-10-03
CN110790789A (zh) 2020-02-14
CN110804072B (zh) 2023-05-12
EA201790328A1 (ru) 2017-08-31
DK3186244T3 (da) 2020-07-13
SG11201701172SA (en) 2017-03-30
EA031106B1 (ru) 2018-11-30
US10822360B2 (en) 2020-11-03
CN110790789B (zh) 2023-05-12
MY198325A (en) 2023-08-24
EP3572410A1 (en) 2019-11-27
PL3186244T3 (pl) 2020-11-16
IL250344A0 (en) 2017-03-30
KR102398714B1 (ko) 2022-05-17
CN110804072A (zh) 2020-02-18
JP2017526677A (ja) 2017-09-14
US20190389890A1 (en) 2019-12-26
MX369649B (es) 2019-11-15
EP3572410B1 (en) 2022-07-20
HRP20201023T1 (hr) 2020-10-16
US20170267705A1 (en) 2017-09-21
IL266766A (en) 2019-07-31
US10336780B2 (en) 2019-07-02
AU2015308988B2 (en) 2018-04-26
PH12017500184B1 (en) 2017-06-28
CA3128645C (en) 2023-06-27
NZ762628A (en) 2023-04-28
DK3572410T3 (da) 2022-08-29
PT3572410T (pt) 2022-09-15
US20210054008A1 (en) 2021-02-25
CA2956251A1 (en) 2016-03-03
AU2015308988C1 (en) 2018-09-06
EA201890648A3 (ru) 2019-02-28
AU2018201980B2 (en) 2019-05-16
BR112017003898B1 (pt) 2022-10-18
ES2927212T3 (es) 2022-11-03
EA033300B1 (ru) 2019-09-30
CN107074826B (zh) 2020-05-22
KR20170046736A (ko) 2017-05-02
CN111269264A (zh) 2020-06-12
US20230382931A1 (en) 2023-11-30
CN107074826A (zh) 2017-08-18
EA201890648A2 (ru) 2018-08-31
PH12017500184A1 (en) 2017-06-28
ES2796089T3 (es) 2020-11-25
US20230117570A1 (en) 2023-04-20
WO2016030335A1 (en) 2016-03-03
US20200239502A1 (en) 2020-07-30
JP2020090535A (ja) 2020-06-11
PT3186244T (pt) 2020-05-29
US11447511B2 (en) 2022-09-20
US20190100541A1 (en) 2019-04-04
EP3186244A1 (en) 2017-07-05
HUE059640T2 (hu) 2022-12-28
KR20200035482A (ko) 2020-04-03
HUE050705T2 (hu) 2020-12-28
IL250344B (en) 2020-01-30
ZA201802864B (en) 2019-07-31
JP6905609B2 (ja) 2021-07-21
US10144750B2 (en) 2018-12-04
CA2956251C (en) 2022-10-25
BR112017003898A2 (pt) 2017-12-05
MY188089A (en) 2021-11-17
NZ729118A (en) 2022-02-25
EP3186244B1 (en) 2020-04-22
JP6663424B2 (ja) 2020-03-11
KR102396905B1 (ko) 2022-05-13
US10654877B2 (en) 2020-05-19

Similar Documents

Publication Publication Date Title
IL266766B (en) Dioxolane analog of uridine for cancer treatment
ZA201704732B (en) Cyclic dinucleotides useful for the treatment of inter alia cancer
IL251560A0 (en) Methods for preparing ribosides
IL259996A (en) Combinations for cancer treatment
SMT202100115T1 (it) Combinazioni di inibitori di fgfr e cmet per il trattamento del cancro
IL248767B (en) Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
IL247859A0 (en) Cancer treatment
ZA201707024B (en) Cancer treatment composition
GB201408297D0 (en) Treatment of cancer
GB201409363D0 (en) Skin cancer treatment
GB201522433D0 (en) Cancer treatment
IL255167A0 (en) Compounds for the treatment of cancer
GB201417456D0 (en) Treatment of cancer
ZA201704589B (en) Compounds for the treatment of cancer
GB201512723D0 (en) Treatment of cancer
GB201507928D0 (en) Treatment of cancer
GB201504617D0 (en) Treatment of cancer
GB201409362D0 (en) Treatment of cancer
GB201405449D0 (en) Treatment of cancer
GB201405075D0 (en) Treatment of cancer
GB201411884D0 (en) Cancer therapy